India, July 1 -- Morepen Laboratories has commenced commercial supplies under its Rs 825 crore Contract Development and Manufacturing Organisation (CDMO) mandate, with the first dispatch worth nearly Rs 50 crore completed during Q1 FY27.
The company said the milestone marks the successful transition of the project from the validation and qualification phase to commercial execution. Morepen expects to deliver an additional Rs 225 crore worth of supplies in Q2 FY27, subject to customer schedules and regulatory approvals.
To support growing CDMO opportunities, the company is expanding its manufacturing capacity, with total reactor capacity expected to reach 600 KL by the end of Q2, followed by phased expansion to 800 KL and 1,000 KL.
Managi...